Obsidian Therapeutics to Present Preclinical Data from cytoDRiVE® Platform and Pipeline at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022
November 7, 2022Read More
Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
October 27, 2022Read More
Join Our Team
Join our collaborative team of innovators who are motivated by a sense of urgency to help patients in need.
Our collective knowledge, capabilities, intellect and energy is our greatest strength.